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Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial pneumonia, which presents with a 
progressive worsening dyspnea, and thus a poor outcome. The members of the Korean Academy of Tuberculosis and 
Respiratory Diseases as well as the participating members of the Korea Interstitial Lung Disease Study Group drafted 
this clinical practice guideline for IPF management. This guideline includes a wide range of topics, including the 
epidemiology, pathogenesis, risk factors, clinical features, diagnosis, treatment, prognosis, and acute exacerbation of IPF 
in Korea. Additionally, we suggested the PICO for the use of pirfenidone and nintendanib and for lung transplantation for 
the treatment of patients with IPF through a systemic literature review using experts’ help in conducting a meta-analysis. 
We recommend this guideline to physicians, other health care professionals, and government personnel in Korea, to 
facilitate the treatment of patients with IPF.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is the most common 
idiopathic interstitial pneumonia (IIP), which is character-
ized by progressively worsening dyspnea and decreased lung 
function. It occurs mainly in the elderly and in men1. After 
the 2002 American Thoracic Society/European Respiratory 
Society (ATS/ERS) guideline, an official guideline revision was 
provided in 2011 by the American Thoracic Society/Euro-
pean Respiratory Society/Japanese Respiratory Society/Latin 
American Thoracic Association (ATS/ERS/JRS/ALAT), which 
deals with the diagnosis and management of IPF1,2. In the 
past, there was no proven agent for IPF, but now, some helpful 
medications for its management are available3.
Since the publication of the 2011 guideline, more studies 
were performed regarding the treatment of IPF. In the 2011 
guideline, for pirfenidone, “conditional recommendation 
against use” was included; however, this became “conditional 
recommendation for use” in the 2015 clinical practice guide-
line, which was reported by ATS/ERS/JRS/ALAT. Further-
more, nintendanib was the conditionally recommended agent 
in the 2015 guideline3.
Korean Interstitial Lung Disease Study Group performed a 
national survey about IIP in 2008. According to this 2008 IIP 
National Survey, 1,685 patients (77.1%) were diagnosed with 
IPF4. Although IPF is the most common form of IIP, there has 
been no guideline in Korea to date concerning the manage-
ment of IPF. In this guideline, we discussed the many aspects 
of IPF: epidemiology, pathogenesis, risk factors, clinical fea-
tures, diagnosis, treatment, prognosis, and acute exacerba-
tion of IPF. Furthermore, we conducted a meta-analysis, and 
suggested PICO for the use of pirfenidone and nintendanib 
and for lung transplantation for the treatment of IPF. We rec-
ommend this guideline to physicians, other health care pro-
fessionals, and government personnel in South Korea, for the 
care of IPF patients.
Epidemiology of Idiopathic  
Pulmonary Fibrosis
IPF is the most common and severe form of IIP. IPF preva-
lence and incidence varies according to regions and countries. 
Its prevalence rate is reported from 0.7 to 63.0 per 100,000 
population, with most studies reporting about 10 per 100,000 
population5-10. The annual incidence is also reported from 0.6 
to 10.7 per 100,000 population5,7. One of the important rea-
sons for these variations in outcome is that many studies were 
conducted in western countries before the establishment of 
the revised IPF diagnostic criteria in 20115,6,8,9,11. According to 
the 2008 IIP National Survey in Korea, 1,685 out of 2,186 pa-
tients (77.1%) with IIP were diagnosed with IPF, from 2003 to 
20074. Another study reported the annual incidence of IPF in 
Korea as 1.7 per 100,000 population12.
The prevalence and incidence of IPF tend to be higher in 
males than in females, and tend to increase with aging. Initial 
diagnosis of IPF is most common in people aged 70 years and 
above8,13,14. In a national study, 1,220 of the 1,685 IPF patients 
(72.4%) were male and the mean age at diagnosis was 69 
years4. The association between exposure to various external 
environmental substances and the occurrence of IPF has been 
reported4. With smoking, both past and present smoking were 
reported to be associated with IPF15. In one study, the relative 
risk of IPF occurrence in smokers was 2.94 times higher than 
healthy adults14.
Livestock, wood dust, metal dust, stones, and diesel particu-
lates are also reported to be associated with IPF9,16. Lee et al.17 
showed that IPF patients with dust exposure are diagnosed 
with IPF at lower ages and had longer respiratory symptom 
compared with IPF patients without dust exposure. In their 
study, dust exposure was identified as a risk factor associated 
with death. Recently, IPF has been reported to be associated 
with other diseases, including reflux esophagitis, diabetes mel-
litus, pulmonary tuberculosis, non-tuberculosis disease, heart 
disease, lung cancer, and chronic obstructive pulmonary dis-
ease18-20. In addition, the association of viral disease with IPF 
was also suggested. Herpesviruses such as Epstein-Barr virus/
cytomegalovirus were detected frequently in the lung tissue of 
IPF patients21,22. Furthermore, the positivity of serum hepatitis 
C virus antibodies has been reported to be high in patients 
with IPF23, and its relevance has been suggested, but there is 
still insufficient evidence to explain the causal relationship.
Definition and Pathogenesis of 
Idiopathic Pulmonary Fibrosis
1. Definition of IPF
IPF is defined as a “specific form of chronic, progressive 
fibrosing interstitial pneumonia of unknown cause, occurring 
primarily in older adults, limited to the lungs, and associated 
with the histopathologic and/or radiologic pattern of usual in-
terstitial pneumonia (UIP).” The definition of IPF requires the 
exclusion of other forms of interstitial pneumonia including 
other idiopathic interstitial pneumonias and interstitial lung 
diseases associated with environmental exposure, medica-
tion, or systemic disease1.
2. Pathogenesis of IPF 
1) Introduction 
IPF results from the recurrent injury to epithelial cells 
caused by a variety of exposures, such as cigarette smoke, 
dust, and gastroesophageal reflux (GER). These exposures 
activate abnormal pathways in a genetically predisposed indi-
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vidual or an aged individual, resulting in the failed resolution 
of the wound-healing response24. Growth factors secreted by 
the injured epithelial cells recruit fibroblasts which differen-
tiate into myofibroblasts. Myofibroblasts secrete collagen, 
which accumulates in the extracellular matrix (ECM)24,25. 
2) Epithelium
An early consequence of injury to the alveolar epithelial 
cells (AEC) is the development of an intraalveolar exudate. 
Organization of the intraalveolar exudate leads to alveolar col-
lapse with apposition of the denuded alveolar walls and loss of 
surfactant. Both epithelial and basement membrane injuries 
appear necessary for the development of intraluminal fibrosis. 
Following an injury, type II cells proliferate and differentiate 
into type I cells for reepithelialization of the injured alveoli. In 
IPF, loss of type I cells and marked proliferation of type II cells 
are noted; however, these cells do not appear to reepithelialize 
the alveolar space. This may be due to the continuing abnor-
malities in the basement membrane, which in turn permit the 
migration of mesenchymal cells from the interstitium to the 
alveolar regions of the injured lung. Excessive deposition of 
collagen by mesenchymal cells appears to prevent the reex-
pansion of the collapsed airspace24,25. 
Another well recognized aberrancy of the AEC in IPF pa-
tients may be the overproduction and release of fibrogenic 
cytokines and growth factors. Following epithelial injury, 
progression of fibrosis follows, due to an imbalance between 
many groups of molecules including proinflammatory and 
anti-inflammatory cytokines, fibrogenic and antifibrogenic 
polypeptides, oxidants-antioxidants, and angiogenic and an-
giostatic molecules. Transforming growth factor (TGF)-β1 is 
one of the most potent regulators, and can induce a number of 
growth factors and cytokines to participate in fibrosis24-26. 
(1) Genetics: Genetic predisposition to IPF is supported 
by familial clustering, the occurrence of lung fibrosis in ge-
netic multi-system disorders, and differing susceptibilities in 
humans exposed to similar levels of fibrogenic agents24. Sur-
factant protein C (SPC) and surfactant protein A2 (SPA2) are 
exclusively synthesized by type II AECs. Mutations in these 
two genes have been described in association with IPF24. SPC 
and SPA mutations have been shown to cause incorrect pro-
tein folding and processing, thereby activating the cells’ endo-
plasmic reticulum (ER) stress response27. Telomerases help to 
offset the shortening that occurs during DNA replication. Rare 
mutations in the telomerase genes, telomerase reverse tran-
scriptase (TERT ) and telomerase RNA component (TERC ) 
have been identified in IPF cases28. Even in the absence of 
TERT/TERC mutations, some IPF patients have shorter 
telomeres compared with age-matched controls, suggesting 
that IPF may be a disease of aging29. A common variant in the 
promoter of the gene encoding mucin 5B (MUC5B) on chro-
mosome 11 was present in patients with familial and sporadic 
IPF30. 
(2) ER stress: ER stress occurs when there is an imbalance 
between cellular demand for protein synthesis and the ER’s 
capacity to synthesize, process, and package the requisite pro-
teins. In response to this stress, the cell activates the unfolded 
protein response (UPR) to match the protein production 
capacity of the ER. ER stress reaction generally helps the cell 
to survive. However, if the stress condition is overwhelming 
or prolonged, and the UPR cannot match the demand, a ter-
minal UPR is activated and the cell sacrifices itself through 
apoptotic pathways27. ER stress and activation of the UPR also 
contribute to fibrotic remodeling in the lungs24,25,31.
(3) TGF-β activation: Levels of active TGF-β are increased 
in the lungs of patients with IPF. Activation of AECs expressing 
integrin αvβ6 induces TGF-β activation. Possible processes 
associated with TGF-β activation include inhibition of AEC 
proliferation, differentiation of fibroblasts to myofibroblasts, 
and activation of programming that promotes epithelial-
mesenchymal transition (EMT)31,32. 
(4) EMT: EMT is the process by which epithelial cells 
acquire molecular and cell physiologic features, commonly 
associated with mesenchymal cells, following activation by 
specific growth factors, of which TGF-β is the prototype. EMT 
programming is activated during tissue injury and remodeling 
conditions. The evidence that alveolar cells exhibit EMT in IPF 
patients is based on studies co-localizing epithelial cell- and 
mesenchymal cell-associated proteins within IPF lungs31,33.
(5) External stressors: To develop IPF, the primary patho-
logic change is a genetic mutation that causes the epithelial 
cells to become intrinsically abnormal. These genetic abnor-
malities lead to activation of molecular pathways such as the 
UPR, TGF-β secretion, and EMT, and ultimately tolung fibro-
sis. However, genetic mutations may not be sufficient to cause 
lung fibrosis; rather, a second event—that is, an environmental 
exposure—may act in concert with a genetically predisposed 
epithelium25,31.
3) Mesenchyme
(1) Fibrocyte: Fibrocytes contribute to the development of 
lung fibrosis by directly producing ECM proteins, by differen-
tiating into fibroblasts or myofibroblasts, or by producing cyto-
kines, which induce collagen deposition. Fibrocytes have been 
found both in the circulation and in the lung parenchyma of 
patients with IPF34. 
(2) Fibroblast: During normal wound healing, unneeded 
fibroblasts are removed through the activation of apoptotic 
pathways. Unlike the normal fibroblasts, IPF fibroblasts resist 
apoptosis and have greater proliferative capacity. Following 
the induction of fibroblast activity by epithelial injury, fibro-
blasts and myofibroblasts appear to organize themselves into 
fibroblastic foci which precede the appearance of end-stage 
fibrosis24,25,31. 
(3) Myofibroblast: Myofibroblasts are cells that express 
features of both fibroblasts and smooth muscle cells, and are 
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identified by their expression of α-smooth muscle actin. Fi-
broblasts differentiate into myofibroblasts under the influence 
of mediators, such as TGF-β. EMT is thought to be another 
source of myofibroblasts31,33. Compared with the resident lung 
fibroblasts, myofibroblasts secrete excessive amounts of ma-
trix. They localize to fibroblastic foci, and are responsible for 
the synthesis and deposition of ECM and the resultant struc-
tural remodeling24,25,31.
(4) Collagen: In the lungs of patients with IPF, excess col-
lagen is deposited in the ECM. Collagen is also degraded ex-
tracellularly by a family of matrix metalloproteinases (MMPs). 
Pathologic fibrotic scars may represent an improper balance 
between deposition and degradation of ECM components. 
However, this concept is not only insufficient but probably 
wrong. The basement membrane, which forms the ECM 
underlying the epithelium and endothelium of parenchymal 
tissue, precludes direct access to the damaged tissue. To 
disrupt this physical barrier, MMPs cleave one or more ECM 
constituents allowing the extravasation of cells into, and out 
of, damaged sites. MMPs may have beneficial and detrimental 
effects, and some individual MMPs such as MMP1 and MMP7 
contribute to the progression and poor outcome of IPF while 
others such as MMP19 seems to be protective24,25,31,35.
(5) The clotting cascade: The clotting cascade appears to 
be activated in pulmonary fibrosis. Cleaved clotting factors 
have major pro-inflammatory and profibrogenic effects, and 
activated platelets/endothelial cells release fibrogenic media-
tors, including platelet-derived growth factor (PDGF) and 
TGF-β36. 
4) Epigenetics
Exposure to environmental stresses such as tobacco smoke, 
air pollution, and aging can lead to epigenetic DNA changes in 
IPF lungs37. DNA methylation and/or other epigenetic chang-
es are important in the pathogenesis of IPF and their enduring 
influences on gene expression could in part explain the relent-
less progression of the illness31.
Risk Factors for Idiopathic  
Pulmonary Fibrosis
IPF could be due to complex interactions between genetic 
predisposition, environmental factors, and pulmonary infec-
tion1,38. Therefore, therapeutic agents are being developed 
focusing on progress rather than disease initiation. Here are 
some major known risk factors.
1. Age and sex
The average age of IPF diagnosis is about 65 years8. The 
reason for not recommending surgical biopsy as a method of 
confirmation of recent IPF is because of the age at the time of 
IPF diagnosis and the accumulation of experience with typi-
cal high-resolution computerized tomography (HRCT) find-
ings1,39. Aging is a major risk factor of IPF based on epidemio-
logical evidence from the mean age at diagnosis, as well as the 
experimental results showing that alveolar damage is not well 
cured by cellular senescence. Abnormal short telomeres were 
observed in the alveolar epithelium of patients with IPF29, 
and telomerase (an enzyme that maintains telomere length) 
mutations, were found in familial IPF28. Aging does not effec-
tively result in protein folding in the ER40. Finally, pathologic 
accumulation of unfolded protein increases ER stress and 
apoptosis. These proteins and apoptosis were increased in 
the alveolar epithelium of IPF patients41,42. In familial IPF, ab-
normalities, in the process of making SPA2, have been found, 
which causes unfolded protein to accumulate43. In addition, 
aging oxidizes proteins such as glutathione and modifies the 
function of mesenchymal stem cells, leading to abnormalities 
in the alveolar epithelial regeneration44,45. 
The incidence and prevalence of IPF is higher in men than 
in women (1.6:1 to 2:1)8, but the prognosis in women is bet-
ter46. It is likely that IPF is common in men because they have 
relatively high smoking rates and are engaged in occupations 
that exposes them to inhaled substances. 
2. Environmental factor
1) Smoking
Exposure to inhaled substances is an important risk factor 
of IPF, and smoking is the most common15. In particular, the 
risk of IPF increases with more than 20 pack-years of smok-
ing, and the risk of IPF due to smoking correspond to both 
familial and sporadic IPF47. The fact that IPF risk persists after 
cessation of smoking suggests that inflammation persists after 
smoking cessation48,49. Smoking itself causes not only epithe-
lial cell damage but also widespread genetic alterations such 
as chromatin transformation and DNA methylation, which 
regulates the gene expression involved in tissue healing pro-
cesses50. However, it has been reported that metal dust (brass, 
lead, and steel), wood dust (pine), farming, raising birds, cos-
metology, masonry, and exposure to plant dusts and animal 
hairs are also related to IPF16. 
2) Infection
Infection is the most common cause of inflammatory 
reaction, which is considered to be a major factor in the de-
velopment and progression of pulmonary fibrosis because 
it initiates alveolar damage and sustains the inflammatory 
response51. Numerous viruses and bacteria can cause epithe-
lial cell damage and apoptosis and can modulate the host im-
mune response52. The infection experimentally contributes to 
the onset of IPF by accelerating fibrosis, with other fibrogenic 
factors53,54. In the past, immunosuppressive therapy for IPF 
was not effective, and clinical evidence of persistent inflam-
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mation was insufficient, suggesting that the role of chronic 
inflammation in the pathogenesis of IPF was minimal55. How-
ever, it cannot be denied that inflammatory cytokines and im-
mune cell infiltration are found in the lungs of IPF patients56. 
Animal experiments have shown that interleukin-1β induces 
early inflammation and fibrosis through TGF-β1, and sustains 
the aggregation of myofibroblasts and collagen at day 60, ir-
respective of the presence of residual inflammation, resulting 
in tissue changes similar to the myofibroblastic foci observed 
in humans57. It is thought that fibrosis progresses due to the 
complex interactions between initial injury and the adverse 
reaction of the healing process, resulting in IPF. 
3. Genetic factors
IPF is considered to be a complex genetic disorder associ-
ated with at least 11 mutations in the nucleotide sequence of 
seven genes (MUC5B , TERT , TERC , RTEL1 , PARN , SFTPC , 
and SFTPA2)58. MUC5B mutation, which causes abnormali-
ties in the mucociliary function of the peripheral airways, ac-
counts for 30%–35% of the risk of IPF58. Among the total IPF 
patients, 1% of surfactant gene mutation, 35% of promoter 
mutation of MUB5B mucin gene, 3% of telomerase gene mu-
tation, and no known gene mutation in the remaining 60% 
of patients were reported30,31,59. Surfactant protein and mucin 
gene mutations result in a direct epithelial cell damage and 
apoptosis43,59, while telomerase gene mutations lead to an ab-
normal recovery pathway after epithelial damage28. 
4. Gastroesophageal reflux
It is known that the prevalence of GER is higher in patients 
with IPF compared to the general population19. Repeated mi-
croaspiration can cause fibrosis by continuing lung injury60,61. 
Although there have been reports that the treatment of GER 
slows the progress of IPF62, recent studies have shown that 
antacid therapy or surgery for GER does not slow down the 
progress of IPF63,64.
Clinical Features and Diagnosis of 
Idiopathic Pulmonary Fibrosis
1. Clinical features of IPF 
IPF should be considered in patients with the following 
clinical features:
- Age over 50 years
- Persistent dyspnea on exertion
- Persistent cough
- Clubbing of the fingers
- Bilateral inspiratory crackles on auscultation
-  Restrictive ventilatory defect with decreased diffusion ca-
pacity
2. Definition of UIP Pattern
1) UIP pattern: HRCT features 
UIP is characterized on HRCT by the presence of reticular 
opacities, often associated with traction bronchiectasis (Fig-
ure 1). Honeycombing is common and is critical in making a 
definitive diagnosis. The distribution of UIP on HRCT is basal 
and subpleural predominance. Micronodules, air trapping, 
discrete cysts, extensive ground glass opacities more than the 
reticulation, consolidation, or peribronchovascular distribu-
tion should be considered an alternative diagnosis. 
In patients whose HRCT does not show a UIP pattern, surgi-
cal lung biopsy is necessary to make a definitive diagnosis. 
(1) UIP pattern (all four criteria)
-  Subpleural, basal predominance
-  Reticular abnormality 
-  Honeycombing±traction bronchiectasis
-  Absence of features that are inconsistent with the UIP pat-
tern
(2) Possible UIP pattern (all four criteria)
-  Subpleural, basal predominance
-  Reticular abnormality 
-  Absence of features that are inconsistent with the UIP pat-
tern
2) UIP pattern: histopathology features
The most important histopathologic finding is a hetero-
geneous appearance at low magnification in which areas of 
fibrosis and honeycomb change alternate with areas of less af-
fected or normal parenchyma. These histopathologic changes 
affect the subpleural and paraseptal parenchyma. The fibrotic 
area is composed of dense collagen and fibroblastic foci. 
Hyaline membranes, organizing pneumonia, granulomas, 
marked interstitial inflammation, and predominant airway 
centered changes should be considered as an alternative diag-
nosis (Figure 2).
(1) UIP pattern (all four criteria)
-  Evidence of marked fibrosis/architectural distortion±honey-
combing in a predominantly subpleural/parasepatal distri-
bution
-  Presence of patchy involvement of the lung parenchyma 
by fibrosis
-  Presence of fibroblast foci
-  Absence of features against the diagnosis of UIP suggesting 
an alternative diagnosis
(2) Probable UIP pattern 
-  Evidence of marked fibrosis/architectural distortion±honey-
combing in a predominantly subpleural/parasepatal distri-
bution
-  Absence of either patchy involvement or fibroblast foci, but 
not both
Korean guideline for IPF
https://doi.org/10.4046/trd.2018.0091 107www.e-trd.org
-  Absence of features against the diagnosis of UIP suggesting 
an alternative diagnosis
Or
-  Honeycomb change only
(3) Possible UIP pattern 
-  Patchy or diffuse involvement of the lung parenchyma by 
fibrosis, ±interstitial inflammation
-  Absence of other criteria for UIP
-  Absence of features against the diagnosis of UIP suggesting 
an alternative diagnosis
3. Diagnosis of IPF 
IPF is associated with the histopathological and/or HRCT 
pattern of UIP1. 
The diagnosis of IPF requires:
-  Exclusion of other known causes of interstitial lung disease 
(ILD) 
-  The presence of a UIP pattern on HRCT in patients who 
have not been subjected to surgical lung biopsy 
-  Specific combination of HRCT and surgical lung biopsy 
pattern in patients subjected to surgical lung biopsy. 
Figure 2. Surgical lung biopsy specimen demonstrating usual interstitial pneumonia pattern (Courtesy from Yonsei University, College of Pa-
thology Prof. Sim HS).
Figure 1. High resolution computed to-
mography images demonstrating usual 
interstitial pneumonia (arrows) (A) and 
possible usual interstitial pneumonia 
(arrows) (B) (Courtesy from Ulsan Col-
lege of Medicine, Asan Medical Center, 
Internal Medicine, Prof. Song JW).
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The accuracy of the diagnosis of IPF increased with multi-
disciplinary discussions between pulmonologists, radiologists, 
and pathologists who have experience at diagnosing ILD65.
Treatment of Idiopathic  
Pulmonary Fibrosis
The treatment of IPF was described according to an official 
ATS/ERS/JRS/ALAT clinical practice guideline: treatment of 
idiopathic pulmonary fibrosis: an update of the 2011 clinical 
practice guideline (Table 1)3. 
For the treatment of IPF, there is a strong recommendation 
against the use of the following: anticoagulation (warfarin), 
imatinib (a selective tyrosine kinase inhibitor against PDGF 
receptors), combination prednisone, azathioprine, and N-
acetylcysteine, and selective endothelin receptor antagonist 
(ambrisentan). Furthermore, for the treatment of IPF, there is 
a conditional recommendation against the use of the follow-
ing agents: phosphodiesterase-5 inhibitor (sildenafil) and dual 
endothelin receptor antagonists (macitentan, bosentan). N-
Acetylcysteine monotherapy and antacid therapy were left 
unchanged from the 2011 guideline. However, for the treat-
ment of IPF, there is a conditional recommendation for the 
use of the following agents: nintedanib (tyrosine kinase inhibi-
tor that targets multiple tyrosine kinases) and pirfenidone.
According to the 2015 international guideline, The Korean 
ILD guideline group selected PICOs concerning pirfenidone, 
nintedanib, and lung transplantation, for the treatment of IPF, 
from systemic literature review.
1. PICO for the treatment of patients with IPF
PICO 1: Does pirfenidone reduce the decrease in forced vi-
tal capacity (FVC) in patients with IPF?
PICO 2: Does nintedanib reduce the decrease in FVC in pa-
tients with IPF?
PICO 3: Does lung transplantation improve the survival in 
patients with IPF compared with medical treatment?
2. Summary of the recommendations for the treatment 
of patients with IPF
-  We suggest that clinicians use pirfenidone in patients with 
IPF to reduce the decrease in FVC (strong recommenda-
tion, high confidence in estimates of effect).
-  We suggest that clinicians use nintedanib in patients with 
IPF to reduce the decrease in FVC (strong recommenda-
tion, high confidence in estimates of effect).
-  We suggest lung transplantation in patients with IPF at ap-
propriate times to improve survival (strong recommenda-
tion, moderate confidence in estimates of effect).
In collaboration with Dr. Hyun Jung Kim (Korea University), 
a clinical guideline special scientist, we designed a search 
strategy using medical subject heading keywords and text 
words (see online supplement), limited to human studies, 
nonindexed citations, and articles either in English or in any 
language with English abstracts. Literature searches for pir-
fenidone, nintedanib, and lung transplantation clinical trials, 
published up to September 2016, were carried out on four 
databases (MEDLINE, EMBASE, COCHRANE library, and 
KoreaMed). 
Table 1. Comparison of recommendations in the 2015 and 2011 idiopathic pulmonary fibrosis guidelines (modified)
Recommendation 2015 Guideline 2011 Guideline
Strong against use Anticoagulation (warfarin), imatinib, selective TKI against 
PDGF receptors
Combination PL+AZA+NAC
Selective ERA (ambrisentan)
Dual ERAs (macitentan, bosentan)
Conditional against use Phosphodiesterase-5 inhibitor (sildenafil)
Dual ERAs (macitentan, bosentan)
Anticoagulation (warfarin), 
Combination PL+AZA+NAC
Pirfenidone
NAC monotherapy
Anti-PH therapy
Conditional use Nintedanib, a TKI targets multiple TKs 
including VEGF, FGF, and PDGF receptors
Pirfenidone
Antiacid therapy
Antiacid therapy
Deferred next update LTX; single vs bilateral LTX NA
TKI: tyrosine kinase inhibitor; PDGF: platelet derived growth factor; PL: prednisone; AZA: azathioprine; NAC: N-acetylcysteine; ERA: en-
dothelin receptor antagonist; PH: pulmonary hypertension; TK: tyrosine kinase; VEGF: vascular endothelial growth factor; FGF: fibroblast 
growth factor; LTX: lung transplantation; NA: not available.
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3. Pirfenidone: PICO1 summary
In order to develop Korean Interstitial Lung Disease guide-
line, we performed a systematic review and meta-analysis on 
the treatment efficacy of pirfenidone (1,800 mg or 2,403 mg 
daily). The end-point was the number of patients who had a 
decrease in vital capacity (VC) or FVC with more than 10% 
decline (Figure 3). 
A total of 1,092 articles, after removal of duplicates, were 
screened. Among them, 31 articles were eligible for the full-
text review, which revealed three studies (Japan study, CA-
PACITY, and ASCEND trials) that were finally included for 
qualitative and quantitative analyses. 
Japan study66 was a phase-3, randomized controlled, multi-
center prospective study conducted for 52 weeks. The primary 
endpoint of this study was change in VC. The mean changes 
in VC were –0.16 L and –0.09 L in the placebo and pirfenidone 
groups, respectively. The numbers of patients with a decrease 
in VC of 10% or more were 54/104 (51.9%) and 37/108 (34.2%) 
in the placebo and pirfenidone groups, respectively. 
CAPACITY67 was a phase-3, two replicated, 72-week, ran-
domized double blind, multicenter trial. Since CAPACITY 
consisted of two separate trials (studies 004 and 006), overall, 
four trials were actually analyzed in this review. The primary 
endpoint was change in FVC at week 72. In study 004, mean 
FVC change at week 72 was –8.0% (standard deviation [SD], 
16.5) in the pirfenidone 2,403 mg/day group and –12.4% (18.5) 
in the placebo group (difference, 4.4%; 95% confidence inter-
val [CI], 0.7–9.1); 35 of 174 (20%) versus 60 of 174 patients 
(35%), respectively, had a decline of at least 10% (difference, 
4.4%; 95% CI, 0.7–9.1). In study 006, mean change in FVC at 
week 72 was –9.0% (SD, 19.6) in the pirfenidone group and 
–9.6% (19.1) in the placebo group, and the difference between 
groups in predicted FVC change at week 72 was not signifi-
cant (0.6%, –3.5 to 4.7).
ASCEND trial68 was a phase-3, randomized controlled, 
multicenter prospective study conducted for 52 weeks. The 
primary end point was the change in FVC or death at week 52. 
FVC decline at week 52 was –280 mL in the placebo and –164 
mL in the pirfenidone group (absolute difference, 116 mL; rel-
ative difference, 41.5%; p<0.001). The number of patients who 
had a decrease in FVC of 10% or more was 88/277 (31.8%) in 
placebo, and 46/278 (16.5%) in pirfenidone group.
Risk of bias from the three studies was low. Quality of the 
evidence was moderate. 
In conclusion, we found four trials in three studies that pro-
spectively analyzed the efficacy of pirfenidone in terms of the 
lung function (FVC). This review revealed that pirfenidone 
delayed the disease progression by retarding the rate of FVC 
decline.
Figure 4. Difference in annual forced vital capacity decline rate between nintedanib and placebo groups. CI: confidence interval.
Figure 3. Forest plot of the risk difference of percentage of study population with forced vital capacity decreased by more than 10%. CI: confi-
dence interval.
SH Lee et al.
110 Tuberc Respir Dis, Respir Dis 2019;82:102-117 www.e-trd.org
4. Nintedanib: PICO2 summary
A systematic review and meta-analysis, on the treatment 
efficacy of nintedanib (150 mg, twice daily) was conducted in 
order to evaluate the annual FVC decline rate by nintedanib 
in patients with IPF (Figure 4). Among 407 articles, three tri-
als from two studies (INPULSIS and TOMORROW)69,70 were 
eligible for our review. In the pooled analysis, the difference 
in annual rates of FVC decline between the two groups was 
–111.9 mL (95% CI, –144.3 to –79.5; p<0.001), which indicated 
that nintedanib slowed the rate of FVC decline. In addition, 
the number of patients with over 10% or 200 mL reduction in 
FVC from the baseline was lower in nintedanib group (risk 
ratio, 0.59; p<0.001). Risk of bias from both studies was low. 
However, both studies had high withdrawal rate, and the qual-
ity of the evidence was moderate. In conclusion, nintedanib 
could delay disease progression by retarding the rate of FVC 
decline.
5. Lung transplantation: PICO3 summary
Given the progressive and incurable nature of IPF, lung 
transplantation is commonly considered in patients with 
moderate to severe disease. Due to the lack of randomized 
controlled trial evidence to guide this recommendation, we 
considered observational studies which assessed the survival 
of patients with IPF, with or without lung transplantation wait-
ing cohort (Figure 5).
We selected two articles and one abstract through extensive 
review of literature.
Riddell et al.71 showed that for those patients on the lung 
transplant waiting list, who did not receive a transplant, sur-
vival was unfortunately poor (75% at 6 months, 30% at 12 
months, and 15% at 18 months). However, following trans-
plantation, all-age survival was 96.6% at 1 year, 90.1% at 2 
years, and 78.9% at 5 years. The 5-year survival of those trans-
planted over the age of 65 was 88.9% (n=9)72.
Thabut et al.72 reported that 28 patients underwent lung 
transplantation (27 single and 1 double), 16 patients died 
while waiting, and two patients remained on the active wait-
ing list. Survival after lung transplantation was 79.4% at 1 
year, 63.5% at 2 years, and 39.0% at 5 years. The multivariable 
analysis showed that lung transplantation reduced the risk of 
death by 75% (95% CI, 8%–86%; p=0.03) after adjustment for 
potential confounding variables72.
Meta-analysis showed that lung transplantation improved 
survival 26 times compared to not having received transplan-
tation in patient with IPF.
Prognosis of Idiopathic  
Pulmonary Fibrosis
1. Natural history of IPF
IPF is a chronic progressive pulmonary disease with an 
average life expectancy of about 3 years73. Most causes of 
death in IPF are due to IPF itself (progression into respiratory 
failure)6. Natural history of IPF is very diverse, and individual 
disease course is difficult to predict. There are also numerous 
fibrotic lung diseases which share clinical features with IPF, 
but are clearly differentiated pathologically and show different 
prognosis. Therefore, clear diagnosis of IPF via multidisci-
plinary integration of clinical, radiological, and useful histo-
logic material is necessary. Moreover, even after definitive 
diagnosis, there is individual variability in the disease course. 
Thus, it is very difficult for clinicians to predict the future prog-
nosis in individual patients at the time of diagnosis. 
Rapid deterioration can occur at any time in the disease 
course of IPF and it can be attributed to known causes such 
as infections or unknown; and, it is defined as “acute exacer-
bation.” Approximately 5%–10% of patients experience acute 
exacerbations each year1, and it is the most important cause 
of hospitalization and death in IPF patients74. A domestic 
prospective study that analyzed 461 IPF patients showed a 
significantly shorter survival (15.5 months vs. 60.6 months 
postdiagnosis) and lower 5-year survival (18.4% vs. 50%) in 
those who experienced acute exacerbations75. A retrospective 
analysis of IPF patients who were included as control group in 
a large 2 or 3 phase clinical studies reported that the average 
decrease in FVC in IPF reached 0.16 to 0.28 L per year76. 
A number of studies were conducted to confirm the disease 
characteristics useful for prognosis prediction in IPF. Since the 
measurement at baseline alone was insufficient to predict the 
risk of progression, the degree of change in important clinical 
variables in IPF, including pulmonary function, exercise test, 
Figure 5. Difference in survival between lung transplantation and placebo groups. OR: odds ratio; CI: confidence interval.
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and chest computed tomography (CT), were also studied for 
their efficacy77. 
2. Prognostic index and prognostic model
Because predict the prognosis with a single variable in IPF 
is almost impossible78-80, clinical prediction models, with these 
individual variables mixed in, has been proposed81-83.
1) Clinical prognostic index
(1) Comorbidity: Various comorbidities are known to 
be associated with poor prognosis in IPF patients, including 
pulmonary hypertension84, accompanying emphysema85, etc. 
Gastroesophageal reflux disease (GERD) is accompanied in 
up to 87% in IPF patients, microscopic aspiration, from chron-
ic GERD repeatedly induces lung injury and can contribute to 
the exacerbation of IPF19.
(2) Age: Several studies reported that older patients show a 
worse prognosis1,78, but some studies reported similar progno-
sis even in those less than 50 years old86.
(3) Sex: Although there are various reports about the influ-
ence of sex on IPF deaths1,78, in one study including 215 pa-
tients, women showed remarkably longer survival compared 
to men even after adjusting for age, smoking history, diffusing 
capacity, and maximum desaturation area46.
(4) Smoking history: Smoking is associated with both in-
creased and decreased mortality in IPF patients38,79. 
(5) Body mass index: A low body mass index can be an 
index of poor nutrition and increased energy expenditure at 
both baseline and during exercise. It shows a significant cor-
relation with lower survival87.
(6) Severity of dyspnea: Degree of dyspnea at diagno-
sis and dyspnea progression according to the time period 
seemed to be related to mortality88.
(7) Oxygen therapy: Irrespective of VC or the 6-minute 
walking distance (6MWD), the higher the oxygen demand to 
maintain percutaneous oxygen saturation at rest in over 96% 
of IPF patients, the higher the mortality rate89. 
(8) Baseline pulmonary function: The most common 
pulmonary function indices showing correlation with progno-
sis are FVC, total lung capacity (TLC), and diffusing capacity 
for carbon monoxide (DLCO)90.
(9) Decline in pulmonary function: Changes in pulmo-
nary function show superior predictive power than baseline 
pulmonary function. Decrease in FVC at 6 or 12 months reli-
ably predicted death90,91. Predictive accuracy is higher when 
using FVC decreases of over 10% as significant threshold rath-
er than the absolute change in FVC92. The decrease in DLCO 
is also associated with increased mortality93, and [P(A–a)O2] 
decrease >15 mm Hg at 12 months is also related to mortal-
ity94.
(10) The 6MWD: The 6MWD at diagnosis and changes in 
6MWD can predict mortality. In one study, baseline 6MWD 
below 250 m and decrease in 6MWD over 50 m at week 24, 
was reported as an independent predictor of death. However, 
the predictive value of the 6MWD is limited due to lack of ap-
propriate standardization95.
(11) Acute exacerbation: Acute exacerbation of IPF is re-
lated to higher mortality96.
2) Radiological, histopathological, and serum predic-
tors
Chest HRCT is a standard imaging test in the evaluation of 
IPF, providing diagnostic and predictive information. Fibrosis 
and honeycomb extent observed in chest HRCT have shown 
correlation with FVC and DLCO%, thus predicting mortal-
ity97. The automated quantified volumes of lung parenchymal 
abnormalities observed in chest HRCT can also predict mor-
tality98. In terms of histopathologic predictors, increased fibro-
blastic foci showed increased mortality99. Some proteins in cir-
culating blood have been reported as associated with survival 
in IPF1,78, but the role as a biomarker of prognosis prediction 
has not been fully verified. Five proteins (matrix metallopro-
teinase 7, intercellular adhesion molecule 1, interleukin-8, vas-
cular cell adhesion molecule 1, and S100A12) were studied 
to confirm survival prediction power by integration of these 
serum predictors and physiological variables together, result-
ing in its efficacy regardless of age, sex, and even baseline lung 
function100. 
3) Composite risk indices
Disease progression and death in IPF is difficult to predict 
due to the high variability of the disease itself. Therefore, a 
number of risk-related indices have been developed. Although 
a composite clinical-radiologic-physiologic score system was 
developed101, it could not be widely used because of the many 
variables which are not routinely measured. 
In addition, Mura et al.102 developed a risk standardization 
tool to predict survival and rapid progression. Medical Re-
search Council Dyspnea Score >3, 6MWD <72% predicted, 
and composite physiologic index >41 were independent pre-
dictors of 3-year survival. And with these, the risk stratification 
score (ROSE) was established.
De Bois et al.83 developed a scoring system using indepen-
dent predictors of mortality from two clinical research data103. 
A simplified model of this includes age, hospitalization due 
to respiratory causes, FVC% predicted, and changes in FVC% 
predicted at week 24. The predictive ability for 1-year survival 
was significantly improved when baseline 6MWD and the 
change in 6MWD at week 24 were added together95.
As a simple but important prognostic model, multidimen-
sional GAP indicator (gender [G], age [A], and two physiologic 
factors: FVC and DLCO [P]) was developed and is in use103. 
The GAP prediction model was verified for prediction accu-
racy of actual mortality even in Japan and Korea104.
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3. Prognostic judgment and assessment recommendations 
in IPF: 2013 NICE guideline
-  Evaluation of the rate of initial clinical deterioration with 
serial pulmonary function test (spirometry test and DLCO) 
to predict the subsequent clinical course and prognosis 
of each patient: at the time of diagnosis, 6 months, and 12 
months after initial diagnosis.
-  If the clinical manifestation deteriorates rapidly, repeat test 
with shorter intervals is necessary.
-  Do not use the 6MWD result at diagnosis for prognosis 
prediction.
-  Respiratory specialists or specialized ILD nursing team 
should provide accurate and clear information including 
test results, clinical diagnosis, and management.
-  When interviewing IPF patient at the time of diagnosis, it 
should include discussion about the expected prognosis in 
a careful manner. At this time, disease severity, average life 
expectancy, the variety of disease course, and the range of 
expected survival, as well as information on the selectable 
treatment methods should be provided.
Acute Exacerbation of Idiopathic 
Pulmonary Fibrosis
1. Definition of acute exacerbation of IPF
According to the results of recent studies, the natural course 
of IPF is not constant105. Some patients experience acute wors-
ening with a gradual decline in pulmonary function, which are 
caused by infection, heart failure, pulmonary embolism, and 
pneumothorax. However, there are cases where the cause is 
unknown despite precise examination106. Acute exacerbation 
is defined as acute and severe respiratory deterioration associ-
ated with new bilateral lung infiltration in IPF patients. Acute 
exacerbation can occur in patients with nonspecific interstitial 
pneumonia, hypersensitivity pneumonitis, and connective tis-
sue disease related interstitial pneumonia107. 
2. Clinical manifestations of acute exacerbation
The main symptom is the deterioration of dyspnea within 
one month. In some patients, fever, cough, increased sputum, 
elevated C-reactive protein, hypoxemia, and neutrophilia in 
bronchoalveolar lavage fluid can be seen108. Diffuse bilateral 
pulmonary infiltration is shown on chest radiography, dif-
fuse alveolar damage, multiple fibroblastic foci, or organizing 
pneumonia can be seen in lung biopsy specimen.
3. Clinical impact of acute exacerbation
Acute exacerbation has a fatal impact on the prognosis of 
the patient. The median survival time after acute exacerbation 
was 22 days to 4.2 months, and the hospital mortality rate was 
reported as 27%–96%106. Also, IPF patients who experienced 
acute exacerbation (median survival time, 15.5 months; 5-year 
survival, 18.4%) have worse outcome than others (median 
survival time, 60.6 months; 5-year survival, 50.0%)75. 
4. Incidence and risk factors of acute exacerbation
The annual incidence of acute exacerbation is known ap-
proximately as 5% to 10%, but variable in many studies (18% 
to 61%)105,106. 
Although the risk factors of acute exacerbation are not well 
known, several studies have shown that pulmonary function 
(FVC, diffusion capacity, TLC), the severity of dyspnea (modi-
fied medical research council scale≥2), the fibrosis extent on 
chest CT, FVC decline at six months, are associated with acute 
exacerbation75,96,105,109. Additionally, bronchoscopy, bronchoal-
veolar lavage, thoracoscopic lung biopsy, and pulmonary 
Figure 6. Diagnostic algorism of acute re-
spiratory deterioration in idiopathic pul-
monary fibrosis patients. IPF: idiopathic 
pulmonary fibrosis; GGO: ground glass 
opacity; CT: computed tomography.
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resection of lung cancer could result in acute exacerbation in 
patients with IPF75,106. 
5. Etiologies of acute exacerbation
The cause of acute exacerbations is not well known, but 
some studies have suggested possibility of deterioration of un-
derlying disease characterized by acute lung injury110,111. Also, 
viral infection, aspiration, and air pollution might contribute to 
the development of acute exacerbation in some patients112-114. 
6. Diagnostic criteria of acute exacerbation
According to international guidelines on the acute exac-
erbation of IPF in 2007, acute exacerbation was defined as 
(1) deterioration of dyspnea within 30 days, (2) new bilateral 
pulmonary infiltration on chest HRCT, and (3) exclusion of 
known causes of acute lung injury (i.e., infection, heart failure, 
and pulmonary embolism) even with detailed examinations 
such as bronchial aspiration or bronchoalveolar lavage analy-
sis. If acute exacerbation is suspected, but all of the above con-
ditions are not met, these conditions are defined as suspected 
acute exacerbation106.
Revised diagnostic criteria of acute exacerbation were 
published in 2016114. The revised definition is an acute, se-
vere respiratory deterioration with new bilateral pulmonary 
infiltration, (1) previous or concurrent diagnosis of IPF, (2) de-
velopment or acute worsening of dyspnea typically less than 
1-month duration, (3) chest CT with new bilateral ground-
glass opacity and/or consolidation on a background pattern 
consistent with the UIP pattern, and 4) deterioration not fully 
explained by heart failure or fluid overload. Similarly, events 
that are clinically considered acute exacerbation but fail to 
meet all four diagnostic criteria are termed as suspected acute 
exacerbations.
In previous diagnostic criteria, acute exacerbation was diag-
nosed when the cause of acute lung injury such as infection or 
aspiration was excluded (idiopathic). However, in the revised 
edition, bilateral pulmonary infiltration except pulmonary 
edema was classified as acute exacerbation regardless of etiol-
ogy. Acute exacerbations are further categorized as triggered 
acute exacerbation (e.g., infection, aspiration, surgery, or drug) 
or idiopathic acute exacerbation (no trigger identified) (Figure 
6). In addition, although the period of occurrence was limited 
to (the development or deterioration of dyspnea within one 
month) in previous edition, revised criteria was changed to 
the time interval from one month to (typically less than 1 
month), which makes the inclusion of suspected cases to be 
acute exacerbation, which was not previously classified owing 
to a period problem.
7. Prevention and treatment of acute exacerbation
To date, the treatment of acute exacerbation has been large-
ly lacking in evidence, only based on case reports or retrospec-
tive cohort studies. The basis of acute exacerbation treatment 
is supportive treatment for acute lung injury. Although there is 
insufficient evidence for drug treatment, giving priority to high 
dose steroid therapy105, cyclosporin A, or warfarin, is recom-
mended; however, afterwards, warfarin has been shown to 
increase the mortality in patients with IPF115. Although these 
are not listed in the recommendation, in some reports, im-
munosuppresants such as cyclophosphamide or tacrolimus, 
and polymyxin B immobilized fiber column hemoperfusion 
were reported to be helpful; prospective studies are needed to 
confirm these results. Recently, pirfenidone and nintedanib, 
which have been shown to be effective in slowing the progress 
of IPF, have also been shown to reduce incidence of acute 
exacerbations, in phase II trials. In some patients, stoppage of 
exposure to air pollution, vaccination, and treatment of GER 
might be helpful in preventing acute exacerbation. Consider-
ing the high mortality, mechanical ventilation is not recom-
mended for severe respiratory failure in patients with acute 
exacerbation, unless lung transplantation is not being consid-
ered.
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